Regulators mull pros, cons of transparency efforts

Regulator transparency has become a rallying cry on both sides of the pond. The European Medicines Agency has been advised by the European ombudsman to reconsider a request for information that it denied two years ago. The case concerns reports of adverse reactions to an acne drug.

In denying the request, the agency had argued that regulations outlining the granting of information excluded adverse event reports. The ombudsman disagreed, stating that the intent of the regulation was to cover all agency documents. In addition, granting the request, by providing greater EMA transparency, would improve Europeans' trust in the agency. It's up to the agency now to consider the ombudsman's recommendation.

In the U.S., as we've reported, the FDA continues its voluntary march toward transparency, led by Commissioner Margaret Hamburg. The regulator is awaiting public comments on 21 draft proposals, culled from 1,500 comments gathered as part of its transparency initiative.

- read the European ombudsman's draft recommendation

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.